INFOVALLEY WELLNESS QUADRANT (IWT)
The INFOVALLEY® Wellness Quadrant (IWQ™) presents a new perspective in the classification of a person‟s health status as it is determined based on a combined knowledge of both the molecular and the clinical condition. It is believed that with the availability of INFOHaem MSS, healthcare system can now be rejuvenated to focus at true wellness and preventive programmes, which promises to maintain the long term health of the people.
Many of the chronic illness such as cardiovascular disease and cancer are multifactorial and linked by preventable risk factors. The key is how to access to these health risk information and intervene even before the clinical symptoms appears. The knowledge gained from molecular predisposition screening and diagnostics combined with clinical risk factor empowers the person to change from a passive role to a proactive participative role in managing their health, as they understand that active co-operation is the key to sustained health. In this entire process, the health progress of the person needs to be monitored on a
regular basis by their physician.
SARS-COv-2 RT-PCR
MOSTFac Mobile Molecular Diagnostics Laboratory for SARS-CoV-2 Detection and Surveillance
MOLECULAR SCREENING SERVICES (MSS)
INFOHaem™ Molecular Screening
INFOHaem™ Molecular Screening Services for FH
INFOHaem™ FH is a Screening, Diagnostic, Pharmacogenomic & Prognostic Test for Familial Hypercholesterolemia. The test evaluates asymptomatic subject‟s lifetime risk of developing Familial Hypercholesterolemia as well as to diagnose hypercholesterolemia patients for being either definite FH or not FH. Molecular examination involves the study (microarray genotyping) of one‟s DNA, in search of mutations and polymorphisms inherited from one‟s parents that confirm the underlying molecular abnormalities for FH. For healthy subject, it detects polymorphisms which predispose an individual to either increased or decreased risk of developing FH. Clinical examination associates one‟s lifestyle choices, family history and medical history to FH risk. The combined clinico-molecular analysis thus provides a more thorough and comprehensive risk assessment than each of the two examinations alone.
The INFOHaem™ FH Chip is based on the polymorphisms in a number of genes involved in lipid metabolism directly or indirectly along the pathway. 1536 variations have been selected from 70 genes with emphasis given to the 3 main genes namely: LDLR (Low-Density Lipoprotein Receptors) gene, ApoB (ApolipoproteinB) gene and PCSK9 (Proprotein Convertase Subtisilin/ Kexin type 9) gene. Other genes include those for pharmacogenomics, associated to effectiveness of statins and their adverse drug reaction like myopathy, as well as genes which are related to certain complications that arise due to elevated cholesterol (such as coronary vascular diseases, myocardial Infarction, ischemic heart diseases and stroke).
INFOHaem™ Molecular Screening Services for 12 Types of Cancer
INFOHaem™ Can12 is a predisposition screening which evaluates a subject‟s lifetime risk of developing 12 prevalent types of cancers. Molecular examination involves the scanning of one‟s DNA, in search of a panel of 768 SNPs inherited from one‟s parents that predispose an individual to either increased or decreased risk of developing cancers. Clinical examination associates one‟s lifestyle choices, family history and medical history to cancer risk.
The 12 types of cancers are:
Breast cancer
Cervical cancer
Colorectal cancer
Gastric cancer
Leukemia
Liver cancer
Lung cancer
Nasopharyngeal cancer
Oral cancer
Ovarian cancer
Prostate cancer
Thyroid cancer
What we stand for
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligule eget dolor. Aenaen massa, Cum soolis natoque penatibus et magnis dis